Poxel SA: Poxel Provides Corporate Update and Reports Cash and Revenue for the Second Quarter and First Half 2022

Cash runway extended through at least February 2023 based upon debt restructuring agreement with IPF Partners (IPF) and equity-linked financing facility with Iris Capital Investment (IRIS)

Related Keywords

Taiwan ,Japan ,Tokyo ,Paris ,France General ,France ,United Kingdom ,Netherlands ,China ,Boston ,Massachusetts ,United States ,Canada ,South Korea ,Maastricht ,Limburg ,British ,Arthur Rouill ,John Kozarich ,Thomas Kuhn ,Merck Serono ,Sumitomo Pharma ,Janice Bourque ,Pierre Legault ,Trademark Office ,International Congress ,Drug Administration ,Financial Press ,Board Of Directors The Company ,Iris Capital Investment ,Orphan Drug Designation ,Solid Form Patent ,Chief Executive Officer ,Fast Track Designation ,X Linked Adrenoleukodystrophy ,Inherited Metabolic Disease ,Experimental Therapeutics ,First Half ,Pharma Agreement ,Following Upcoming ,British Columbia ,Financial Press Release ,Japan Poxel ,Southeast Asian ,Euronext Paris ,Relations Communication Senior Director ,Vice President ,Investor Relations Communication ,Poxel ,Rovides ,Corporate ,Update ,Reports ,Cash ,Revenue ,Second ,Quarter ,First ,Calf ,022 ,